Show simple item record

dc.contributor.authorRaymond, E
dc.contributor.authorDahan, L
dc.contributor.authorRaoul, J
dc.contributor.authorBang, Y
dc.contributor.authorBorbath, I
dc.contributor.authorLombard-Bohas, C
dc.contributor.authorValle, Juan W
dc.contributor.authorMetrakos, P
dc.contributor.authorSmith, D
dc.contributor.authorVinik, A
dc.contributor.authorChen, J
dc.contributor.authorHörsch, D
dc.contributor.authorHammel, P
dc.contributor.authorWiedenmann, B
dc.contributor.authorVan Cutsem, E
dc.contributor.authorPatyna, S
dc.contributor.authorLu, Dongr
dc.contributor.authorBlanckmeister, C
dc.contributor.authorChao, R
dc.contributor.authorRuszniewski, P
dc.date.accessioned2012-01-09T23:09:26Z
dc.date.available2012-01-09T23:09:26Z
dc.date.issued2011-02-10
dc.identifier.citationSunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364 (6):501-13 N. Engl. J. Med.en
dc.identifier.issn1533-4406
dc.identifier.pmid21306237
dc.identifier.doi10.1056/NEJMoa1003825
dc.identifier.urihttp://hdl.handle.net/10541/201093
dc.description.abstractThe multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshDisease Progression
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIndoles
dc.subject.meshIntention to Treat Analysis
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeuroendocrine Tumors
dc.subject.meshPancreatic Neoplasms
dc.subject.meshProportional Hazards Models
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyrroles
dc.subject.meshQuality of Life
dc.subject.meshReceptors, Vascular Endothelial Growth Factor
dc.titleSunitinib malate for the treatment of pancreatic neuroendocrine tumors.en
dc.typeArticleen
dc.contributor.departmentService Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France.en
dc.identifier.journalNew England Journal of Medicineen
html.description.abstractThe multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.


This item appears in the following Collection(s)

Show simple item record